TABLE 2.
ARIA‐E events from Study 201 core and OLE.
| CORE | OLE | |||||||
|---|---|---|---|---|---|---|---|---|
| BAN2401 | BAN2401 | |||||||
| Category |
Placebo (N = 245) N (%) |
2.5 mg/kg Biweekly (N = 52) n (%) |
5 mg/kg Monthly (N = 51) n (%) |
5 mg/kg Biweekly (N = 92) n (%) |
10 mg/kg Monthly (N = 253) n (%) |
10 mg/kg Biweekly (N = 161) n (%) |
Newly treated Core Placebo (N = 45) n (%) |
All treated in OLE (N = 180) n (%) |
| ARIA‐E | 2 (0.8) | 1 (1.9) | 1 (2.0) | 3 (3.3) | 25 (9.9) | 16 (9.9) | 4/45 (8.9) | 14/180 (7.8) |
| ApoE4+ | 2/174 (1.1) | 1/38 (2.6) | 1/40 (2.5) | 3/84 (3.6) | 23/225(10.2) | 7/49 (14.3) | 4/31 (12.9) | 13/125 (10.4) |
| Homozygous | 1/40 (2.5) | 0/5 (0) | 1/12 (8.3) | 1/14 (7.1) | 11/60 (18.3) | 5/10 (50.0) | 1/4 (25.0) | 4/28 (14.3) |
| Heterozygous | 1/134 (0.7) | 1/33 (3.0) | 0/28 (0) | 2/70 (2.9) | 12/165 (7.3) | 2/39 (5.1) | 3/27 (11.1) | 9/97 (9.3) |
| ApoE4‐ | 0/71 (0) | 0/14 (0) | 0/11 (0) | 0/8 (0) | 2/28 (7.1) | 9/112 (8.0) | 0/14 (0) | 1/55 (1.8) |